News and Events

upcoming events
Events
Sep 22
Department of Bioengineering PhD Dissertation Defense: Will Skinner 1:00 p.m.

Will Skinner, a PhD Candidate in Bioengineering at the University of Oregon’s Knight Campus, will present his dissertation, “Developing a Magnetoelastic...
Department of Bioengineering PhD Dissertation Defense: Will Skinner
September 22
1:00–2:00 p.m.
Phil and Penny Knight Campus for Accelerating Scientific Impact Beetham Family Seminar Room

Will Skinner, a PhD Candidate in Bioengineering at the University of Oregon’s Knight Campus, will present his dissertation, “Developing a Magnetoelastic Monitoring System for Tracking Cell Density and Growth Kinetics in Real Time.” This presentation also serves as the opening seminar in the 2025–26 Department of Bioengineering Seminar Series. 

Sep 29
Bioengineering Seminar Series: Andrew Ellington, “Machine Learning for Protein Engineering: Successes and Failures, and How to Tell the Difference”

Andrew Ellington, Professor at the University of Texas at Austin, will present a seminar titled “Machine Learning for Protein Engineering: Successes and Failures, and...
Bioengineering Seminar Series: Andrew Ellington, “Machine Learning for Protein Engineering: Successes and Failures, and How to Tell the Difference”
September 29
Phil and Penny Knight Campus for Accelerating Scientific Impact Beetham Family Seminar Room

Andrew Ellington, Professor at the University of Texas at Austin, will present a seminar titled “Machine Learning for Protein Engineering: Successes and Failures, and How to Tell the Difference.” In this talk, Dr. Ellington will explore the evolving role of machine learning in the field of protein engineering, highlighting both its breakthroughs and limitations.

This event is part of the 2025–26 Bioengineering Seminar Series hosted by the Knight Campus Department of Bioengineering. All members of the university community are welcome to attend.

Oct 6
Bioengineering Seminar Series: Calin Plesa (Promotion and Tenure Talk: “Exploring Biological Sequence Space at Scale”) 1:00 p.m.

Calin Plesa, Assistant Professor in the Department of Bioengineering at the University of Oregon’s Knight Campus, will present his promotion and tenure talk during the...
Bioengineering Seminar Series: Calin Plesa (Promotion and Tenure Talk: “Exploring Biological Sequence Space at Scale”)
October 6
1:00–2:00 p.m.
Phil and Penny Knight Campus for Accelerating Scientific Impact Beetham Family Seminar Room

Calin Plesa, Assistant Professor in the Department of Bioengineering at the University of Oregon’s Knight Campus, will present his promotion and tenure talk during the regularly scheduled Bioengineering Seminar Series. His presentation, titled “Exploring Biological Sequence Space at Scale,” will highlight his lab’s work developing high-throughput methods to investigate how variations in DNA and protein sequences drive biological function.

All are welcome to attend this special seminar.

Nov 6
Robert Family Entrepreneurship Speaker Series with Tom Moss 10:00 a.m.

About the talk: We tend to romanticize tech entrepreneurship, promoting myths of unique visionary founders who see the future and then move heaven and earth to make it...
Robert Family Entrepreneurship Speaker Series with Tom Moss
November 6
10:00–11:00 a.m.
Phil and Penny Knight Campus for Accelerating Scientific Impact Beetham Family Seminar Room

About the talk: We tend to romanticize tech entrepreneurship, promoting myths of unique visionary founders who see the future and then move heaven and earth to make it happen. In reality, entrepreneurship usually involves several pivots, lots of pitfalls, and a good dose of luck. Fortunately, entrepreneurship can be done by anyone, and is something that one can better at with practice and through study. This talk aims to demystify entrepreneurship as a profession and discuss some of the ways entrepreneurs can improve their chances for success.

About Tom Moss: Tom Moss is a seasoned technology executive and serial entrepreneur with a proven track record of building, scaling, and leading innovative companies in the mobile, consumer electronics, and robotics industries. He has founded multiple successful startups including 3LM (acquired by Motorola) and Nextbit (acquired by Razer), and has held senior leadership positions at Google, where he served as the first global head of business development for Android, as well as Motorola, Razer, and Skydio, where he served as the company’s first COO and most recently served as CEO of the APAC region. A prolific inventor with 25 patents, Tom is also an active angel investor in over 40 companies and serves as a Mentor and Entrepreneur-in-Residence at Techstars, is a limited partner in multiple venture capital funds, and sits on the board of multiple deep-tech startups.

BIOE Science Seminars 

UO SCIENCE SEMINARs
Knight Campus News
New research published in Tissue Engineering from the Guldberg lab is creating a model for vascular network regeneration
Danielle Benoit, Lorry Lokey Chair of Bioengineering, has been recognized with the Outstanding Department Chair Award for her dedicated and visionary leadership.

Knight Campus Ph.D. candidate Rose Hulsey-Vincent has been awarded a competitive National Institutes of Health (NIH) Individual Predoctoral Fellowship (F31) to support her research on the neural basis of song in canary birds.

MORE KNIGHT CAMPUS NEWS »

event videos

   
Science Knight Out with Jim Hutchison
How can chemistry help build a better and more sustainable future? That question has long been on Jim Hutchison’s mind.
Meet Kylie Williams
Kylie Williams is making history as the first University of Oregon student to earn a degree in engineering — and one of the first-ever PhD graduates from the Knight Campus’ Department of Bioengineering!
Entrepreneurship Speaker Series with Elliot Reed
Discover the high-stakes journey of commercializing disruptive technologies from research institutions to thriving businesses.
Distinguished Lecture Series with David Mooney
David Mooney discusses how T cell-based therapies are revolutionizing the treatment of some types of cancer, but currently suffer from a number of limitations.